Zimbabwe has turned down a substantial US health deal valued at 367 million US dollars (272 million pounds) over five years due to the United States' demand for sensitive biological samples.
This rejection became public following a internal memorandum dated December was disclosed, which showed Head of State Emmerson Mnangagwa felt the deal was "skewed".
A government representative later clarified that the US was requesting genetic material for scientific study and commercial purposes while was unwilling to guarantee the benefits from any future vaccines.
"We are forced to start the challenging and unfortunate process of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had provided over $1.9bn in health funding to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for continued negotiations to find a agreement suitable to both sides so the country's vital HIV programme can be sustained.
Wider Background
This rejection comes after a similar situation in neighbouring Kenya, where a court suspended a related health funding agreement after concerns were filed about the safety of Kenyans' health data.
Since returning to office last year, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
The agency had managed assistance for the American government, but Trump claimed its spending was "inefficient" and his government was seeking direct bilateral agreements to boost openness and responsibility.
According to reports, 16 nations in Africa have so far signed these new agreements, constituting more than $18.3bn in new funding.
Specifics of the Declined Agreement
The money for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this cooperation could have provided significant advantages for the people of Zimbabwe, especially the 1.2 million currently on antiretroviral therapy via American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana said the arrangement was "unfair".
"Our nation was requested to surrender its biological resources and data over an extended period, with no equivalent guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," he stated.
"Effectively, our country would provide the basic resources for scientific discovery with no certainty that the end products would be available to our people if a new pandemic emerge."
Sovereignty and Global Health
He also pointed out that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were undermining systems already set up via the international health agency.
Mangwana cited its Pandemic Benefit-Sharing system designed to deal with future pandemics.
"This framework is designed to guarantee that when a nation provides its information, the benefits – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to create them."
These objections over the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We encourage continued discussions with our US partners on how future co-operation could be designed in a way that respects the sovereignty and interests of each country."
Health Experts Reaction
Medical experts said it understood the official position, but urged that talks must proceed since a large portion of the nation's HIV programmes relied on international support.
"Where specific concerns arise, such as those involving information security or agreement terms, these can frequently be resolved through detailed discussion and mutually agreed protections," it commented.
The situation emphasises the continuing tensions between receiving crucial foreign assistance and safeguarding local interests in an ever more interconnected world.